Günter Gmeiner

1 month ago | analyticalsciencejournals.onlinelibrary.wiley.com | Christian Reichel |Thomas Filip |Günter Gmeiner |Mario Thevis

1 Introduction ACE-031 (Ramatercept) is a soluble homodimeric fusion protein (ActRIIB-IgG1Fc, 343 amino acids) with three N-glycosylation sites [1], which binds (i.e. “traps” and thus blocks) activin receptor type II B (ActRIIB) ligands including myostatin [2]. Myostatin-inhibition leads to an increase in muscle mass and loss of fat. ACE-031 was primarily developed to treat myopathies in humans (e.g., Duchenne muscular dystrophy) [3].